The process has to begin with investors who are unusually perceptive, unconventional, iconoclastic or early.
What we offer
Investor Portal
Reasons to Invest
Important and unmet medical need
- Celiac Disease and Non-Celiac Gluten Sensitivity are high unmet medical needs.
- No effective medical curatives exist to date.
Untapped markets
- The market size for Celiac Disease and Non-Celiac Gluten Sensitivity have a volume of USD 10.8 bn and USD 19.4 bn, respectively.
- The awareness and diagnoses for both conditions is increasing rapidly, providing a huge opportunity for growth.
High probability of success and mitigated development risk
- Experienced management team and major milestones already achieved
- Validated in vitro proof of concept
- 2-way commercialisation strategy (dietary supplement and drug)
- GRAS notification – fast market entry as dietary supplement in USA
- Strong IP position with patents granted in all major pharma markets
- Lean, effective infrastructure through collaboration with leading third party research, development and pharmaceutical companies
Attractive exit opportunities
- Ongoing M&A discussions
- Trade sale after achievement of human proof of concept for AMY02
- Out-licensing of AMY01 as dietary supplement
Market
Prevalence
1% – 1.5%
Celiac Disease
6% – 10%
Non-Celiac Gluten Sensitivity
Number of individuals affected globally
>
0
m
Celiac Disease
>
0
m
Non-Celiac Gluten Sensitivity
Market Size
USD
0
bn
Celiac Disease
USD
0
bn
Non-Celiac Gluten Sensitivity
Growth Drivers
- Increasing awareness through marketing activities for “gluten free“ products (suboptimal treatment as they contain traces of gluten, sufficient to trigger clinical symptoms)
- Progressive westernization of diets (which mostly includes gluten) and growing replacement of rice by wheat
- Serological biomarkers available for Celiac Disease. Diagnostic tools for Non-Celiac Gluten Sensitivity are under development
- Global gluten free market expected to continue growing at 10.5 % compound annual growth rate until 2020
If you are interested in investing in AMYRA Biotech AG or would like to receive more information on our products and technology, please get in touch with us.
Contact